97191 ⎘
Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
METHODS OF TREATING SJOGREN'S DISEASE
#2NOVEL PEPTIDES
#3SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#4PEPTIDE CONJUGATES AND USE THEREOF TO PROMOTE CAS NUCLEASE IMMUNE TOLERANCE IN GENOME ENGINEERING GENE THERAPY
#5INTRATUMORALLY INJECTED YEAST VACCINE
#6TREATMENT OF AIHA WITH BAFF OR BAFF RECEPTOR INHIBITORY ANTIBODIES
#7IMMUNOGLOBULIN VARIABLE DOMAINS
#8PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
#9DENOSUMAB AND COLCHICINE TO PREVENT BLOOD CANCER AND AGING DISEASE IN PATIENTS WITH CLONAL HEMATOPOIESIS
#10SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#11ANTIBODY MOLECULES TO APRIL AND USES THEREOF
#12SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#13ANTIBODIES THAT BIND OX40L AND ANTIBODIES THAT BIND TSLP IN COMBINATION WITH HYALURONIDASE OR A VARIANT THEREOF
#14TL1A BINDING PROTEINS AND METHODS OF USE
#15LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
#16NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#17CRYSTALLISATION OF A PROTEIN CAPABLE OF CRYSTALLIZING UNDER SALTING-IN CONDITIONS USING MULTIPLE PROTEIN FEEDS
#18CD70 ANTIBODY DRUG CONJUGATES AND METHODS OF USING THE SAME
#19ANTI-TL1A ANTIBODY THERAPEUTIC METHODS
#20ONCOLYTIC VIRUS EXPRESSING AN IMMUNE CELL ENGAGER FOR TUMOR TARGETING
#21CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR THE TREATMENT AND PREVENTION OF SJÖGREN'S SYNDROME
#22ANTI-DRUG ANTIBODY ASSAYS
#23ANTIBODIES AGAINST TL1A AND USES THEREOF
#24CD40L 41BBL BISPECIFIC PROTEINS
#25TL1A BINDING PROTEINS AND METHODS OF USE
#26ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#27SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#28ANTIBODIES TO CD70
#29SINGLE-CHAIN BELIMUMAB ANTIBODY-TRANSFERRIN FUSION PROTEIN FOR ENHANCED EFFICACY AND INDICATIONS
#30NON-GENOTOXIC CONDITIONING REGIMEN FOR STEM CELL TRANSPLANTATION
#31CANCER ANTIGEN TARGETS AND USES THEREOF
#32OX40-Binding Polypeptides and Uses Thereof
#33NOVEL POLYPEPTIDES
#34TREATMENT OF EROSIVE HAND OSTEOARTHRITIS
#35TREATING CANCER WITH CHIMERIC ANTIGEN RECEPTORS THAT BIND TO TRAILSHORT POLYPEPTIDES
#36METHODS INVOLVING DETECTING TNF STIMULATED GENE 6 (TSG-6) FOR IMPROVING ANTI-TUMOR RESPONSES TO IMMUNE THERAPY IN CANCER PATIENTS
#37METHODS FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE WITH AN ANTI-TL1A ANTIBODY
#38AGONISTIC TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES
#39ANTI-TNF-LIKE LIGAND 1A (TL1A) ANTIBODIES
#40Antibodies Against TL1A and Uses Thereof
#41TREATMENT OF ATOPIC DERMATITIS
#42BINDING MOLECULES FOR BCMA AND CD3
#43HOMOGENEOUS ANTIBODY POPULATIONS
#44ANTI-CD30L ANTIBODIES, FORMULATIONS THEREFOR, AND USES THEREOF
#45THERAPEUTIC ANTIBODIES
#46METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY
#47METHODS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS
#48TETRAVALENT BISPECIFIC AND TETRASPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
#49FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME
#50ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE
#51FUSION CONSTRUCTS AND METHODS OF USING THEREOF
#52ANTIBODIES CAPABLE OF SPECIFICALLY BINDING TL1A AND USE THEREOF
#53NOVEL METHODS AND COMPOSITION OF AAV VECTORS FOR THE TREATMENT OF FRIEDREICH'S ATAXIA
#54ENHANCING THE ACTIVITY OF CELLULAR THERAPIES IN THE TUMOR MICROENVIRONMENT
#55RANK-L BINDING MOLECULES
#56METHODS AND MATERIALS FOR MODULATING T CELL ACTIVATION USING TRAILshort POLYPEPTIDES
#57METHODS AND SYSTEMS FOR SELECTION AND TREATMENT OF PATIENTS WITH INFLAMMATORY DISEASES
#58HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS
#59FULLY-HUMAN POST-TRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTICS
#60METHODS AND COMPOSITIONS FOR RE-DOSING AAV USING ANTI-CD40 ANTAGONISTIC ANTIBODY TO SUPPRESS HOST ANTI-AAV ANTIBODY RESPONSE
#61ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
#62GENE USING BCMA EXTRACELLULAR DOMAIN AS MARKER, POLYPEPTIDE, RECOMBINANT EXPRESSION VECTOR, GENETICALLY ENGINEERED CELL, AND USE THEREOF
#63ANTI-TL1A ANTIBODY FORMULATIONS
#64ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS
#65ANTIBODIES, USES & METHODS
#66METHODS AND COMPOSITIONS FOR TREATING CANCER
#67COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING A FAS AXIS ANTAGONIST AND A T-REG CELL DEPLETING AGENT ANTAGONIST
#68COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME
#69ANTI-CD70 NANOANTIBODY AND USE THEREOF
#70CELLS AND COMPOSITIONS FOR TREATING CANCER
#71High Concentratioin Anti-BLYS Pharmaceutical Formulations
#72CELLS EXPRESSING ANTI-CD70 CHIMERIC RECEPTOR AND USES THEREOF
#73CD30 HINGE AND/OR TRANSMEMBRANE DOMAIN-BASED CHIMERIC ANTIGEN RECEPTORS
#74CD70 BINDING CAR-T CELLS COMPRISING CD33 BINDING T-CELL ENGAGING ANTIBODY MOLECULES
#75METHODS OF TREATING INFLAMMATORY DISEASES WITH COMBINATION OF TL1A INHIBITORS AND IL23 INHIBITORS
#76Methods Of Treating Decreased Bone Mineral Density With Cluster Of Differentiation 109 (CD109) Inhibitors
#77ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
#78TREATMENT FOR ACUTE MYELOID LEUKEMIA WITH ANTI-CD70 ANTIBODIES
#79ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
#80EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES (TILS) WITH TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS AND THERAPEUTIC COMBINATIONS OF TILS AND TNFRSF AGONISTS
#81ANTIBODIES THAT SPECIFICALLY BIND TO API5 PROTEIN
#82Anti-NGF Antibodies and Methods Thereof
#83Anti-NGF Antibodies and Methods Thereof
#84ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents
#85BISPECIFIC ANTIBODIES WITH CLEAVABLE C-TERMINAL CHARGE-PAIRED TAGS
#86TRAILshort ANTIBODY AND METHODS OF USE
#87METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA
#88CD70 BINDING MOLECULES AND METHODS OF USE THEREOF
#89RETROVIRAL-LIKE PARTICLE-REDUCED CHINESE HAMSTER OVARY PRODUCTION CELL LINES
#90Antibodies That Specifically Bind to TL1A and Methods of Treating Skin Disease
#91GENETICALLY ENGINEERED T CELLS WITH REGNASE-1 AND/OR TGFBRII DISRUPTION HAVE IMPROVED FUNCTIONALITY AND PERSISTENCE
#92REGULATORY T CELLS WITH CHIMERIC ANTIGEN RECEPTOR TARGETING CO-STIMULATORY MOLECULES TO PREVENT AND/OR TREAT INFLAMMATORY CONDITIONS
#93BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
#94ANTIBODIES FOR PREVENTING THE CLEAVAGE OF CD95L BY METALLOPROTEASES
#95COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT
#96Library of Antigen-Binding Molecules Including Modified Antibody Variable Region
#97ANTI-NGF ANTIBODIES AND METHODS OF TREATING PAIN THEREOF
#98CHIMERIC ANTIGEN RECEPTORS TARGETING CD70
#99TRIPLE COMBINATION ANTIBODY THERAPIES
#100ANTI-DECTIN-1 ANTIBODIES AND METHODS OF USE THEREOF
#101METHOD FOR THE PRODUCTION OF DOMAIN ANTIBODIES
#102CANINE ANTI-NGF ANTIBODIES AND METHODS OF TREATING PAIN THEREOF
#103ANTI-CTLA4/OX40 BISPECIFIC ANTIBODIES AND USES THEREOF
#104TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
#105TL1A ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
#106SELECTABLE MARKERS FOR EUKARYOTIC EXPRESSION SYSTEM
#107METHOD OF TREATING IGA NEPHROPATHY BY ADMINISTERING ALTERED ANTIBODIES WHICH BIND HUMAN A PROLIFERATION-INDUCING LIGAND (APRIL) PROTEIN
#108ANTIBODIES SPECIFICALLY RECOGNIZING FASL AND USES THEREOF
#109BINDING DOMAINS AND METHODS OF USE THEREOF
#110NOVEL DARPIN BASED CD70 ENGAGERS
#111METHODS FOR PRODUCTION OF THERAPEUTIC IMMUNE CELLS HAVING ENHANCED METABOLIC FITNESS AND COMPOSITIONS THEREOF
#112NOVEL MARKERS FOR RECOMBINANT PRODUCTION SYSTEM
#113ANTI-CD70 ANTIBODIES, CONJUGATES THEREOF AND METHODS OF USING THE SAME
#114NUCLEIC ACID MOLECULES ENCODING ANTIBODIES TO A PROLIFERATION-INDUCING LIGAND (APRIL)
#115ANTI-HUMAN PAPILLOMAVIRUS (HPV) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF
#116DOSING AND TREATMENT OF IMMUNE-MEDIATED DISEASES AND BIOMARKERS ASSOCIATED WITH IMMUNE-MEDIATED DISEASES
#117MULTI-SPECIFIC T CELL ENGAGERS COMPRISING LRRC15 ANTIGEN-BINDING DOMAIN
#118ANTIBODY-DRUG CONJUGATE
#119ANTIBODY MOLECULES TO APRIL AND USES THEREOF
#120ANTI-BCMA NANOBODY AND USE THEREOF
#121MULTI-SPECIFIC LIGAND BINDERS
#122ANTIBODIES SPECIFIC FOR CD70 AND THEIR USES
#123COMBINATIONS OF ANTI-INFLAMMATORY AGENTS FOR TREATING ACUTE ORGAN FAILURE, ARDS, ORGANS FOR TRANSPLANTATION OR DISEASES CAUSED BY AN AIRWAY-TARGETING VIRUS
#124Methods of Treating Asthma with Anti-LIGHT Antibodies
#125METHOD FOR OPTIMIZING DRUG SELECTION
#126NEUTRALIZING ANTI-CD95L MONOCLONAL ANTIBODIES
#127Anti-CD70 Antibody Drug Conjugates
#128BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA
#129PROTEIN SIGNATURES FOR DISTINGUISHING BETWEEN BACTERIAL AND VIRAL INFECTIONS
#130OX40-Binding Polypeptides and Uses Thereof
#131CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS
#132TREATMENT OF MULTIPLE SCLEROSIS WITH ANTI-CD40L ANTIBODIES
#133PHARMACEUTICAL FORMULATIONS CONTAINING ANTI-OX40L ANTIBODIES
#134ANTIGEN-BINDING MOLECULE
#135CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS
#136ANTIBODIES WITH MODULATED GLYCAN PROFILES
#137COMPOSITIONS AND METHODS FOR SELECTIVE PROTEIN DEGRADATION
#138CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR THE TREATMENT AND PREVENTION OF SJÖGREN'S SYNDROME
#139DUPLEXBODIES
#140CD40L-SPECIFIC TN3-DERIVED SCAFFOLDS FOR USE IN THE TREATMENT AND PREVENTION OF RHEUMATOID ARTHRITIS
#141OPTIMIZED ANTI-TL1A ANTIBODIES
#142Dosing Regimen of Combination of Anti-CD20 and Anti-BLyS Antibodies
#143GENETICALLY MODIFIED NATURAL KILLER CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY
#144METHOD FOR OBTAINING APRIL-BINDING PEPTIDES, PROCESS FOR PRODUCING THE PEPTIDES, APRIL-BINDING PEPTIDES OBTAINABLE WITH SAID METHOD/PROCESS AND USE OF THE APRIL-BINDING PEPTIDES
#145Antibody Masking Domains
#146ANTI-TL1A ANTIBODY COMPOSITIONS AND METHODS OF TREATMENT IN THE LUNG
#147ANTI CD154 ANTIBODY AND USE THEREOF
#148BACTERIAL STRAIN FOR RELEASING A RECOMBINANT PROTEIN IN A FERMENTATION METHOD
#149HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
#150MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOF
#151Treatment Of Multiple Sclerosis And Neuromyelitis Optica
#152COMPOSITIONS COMPRISING HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
#153CYTOKINE ASSOCIATED TUMOR INFILTRATING LYMPHOCYTES COMPOSITIONS AND METHODS
#154POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-6 AND TNF ALPHA
#155ANTI-CD70 CHIMERIC ANTIGEN RECEPTORS
#156ANTIGEN BINDING MOLECULES THAT BIND LIGHT
#157ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFa BISPECIFIC ANTIBODY, AND USES THEREOF
#158POLYPEPTIDES TARGETING CD70-POSITIVE CANCERS
#159PROTEINS THAT BIND CD80 AND/OR CD86, AND OX40L
#160ATP-dependent agonists of immune cells function as anticancer agents
#161Anti-BAFF Antibodies for use in a Method of Treatment of Long Covid and/or Post-Acute Sequelae SARS-CoV-2 Infection (PASC)
#162ANTI-CD30L ANTIBODIES AND USES THEREOF
#163ANTIGEN BINDING MOLECULE SPECIFICALLY BINDING TO RANKL AND NGF, AND MEDICAL USE THEREOF
#164NOVEL DARPin BASED MULTI-SPECIFIC T-CELL ENGAGERS
#165METHODS OF CELL THERAPIES
#166DEVELOPMENT AND USE OF FUNCTION-ENHANCED ANTIBODY BLOCKING AGENT
#167TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES
#168CD70 ANTI-IDIOTYPE ANTIBODIES
#169MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF
#170MUTATED FERRITIN PROTEIN
#171CLAUDIN 18.2 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS AND USES THEREOF
#172PATIENT SELECTION METHODS AND KITS FOR THERAPIES TARGETING TL1A
#173POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE
#174Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
#175Humanized Anti-CD70 Binding Agents and Uses Thereof
#176METHOD OF TREATMENT OF PATIENTS HAVING REDUCED SENSITIVITY TO A BCL-2 INHIBITOR
#177METHODS OF TREATING CANCER WITH NONFUCOSYLATED ANTI-CD70 ANTIBODIES
#178METHODS OF TREATING CANCER WITH A COMBINATION OF A NONFUCOSYLATED ANTI-CD70 ANTIBODY AND A CD47 ANTAGONIST
#179Methods of Treating Ulcerative Colitis with Anti-LIGHT Antibodies
#180ANTIBODIES COMPRISING MODIFIED HEAVY CONSTANT REGIONS
#181ANTIBODIES AGAINST TL1A AND USES THEREOF
#182ANTI-TIGIT ANTIBODIES AND METHODS OF USE THEREOF
#183ANTIBODIES, USES & METHODS
#184ANTIBODIES, COMBINATIONS COMPRISING ANTIBODIES, BIOMARKERS, USES & METHODS
#185HIGH CONCENTRATION PROTEIN FORMULATIONS WITH REDUCED VISCOSITY
#186Cell-Based Therapeutics Targeting CD70
#187ANTI-APRIL ANTIBODIES AND USES THEREOF
#188DUAL BINDING ANTIBODIES, METHODS OF PRODUCING DUAL BINDING ANTIBODIES, AND USES THEREOF
#189ANTI-CD30L ANTIBODIES AND USES THEREOF
#190ANTIBODY MOLECULES TO APRIL AND USES THEREOF
#191VARIANT TARGET BINDING AGENTS AND USES THEREOF
#192CD40L ANTAGONIST AND USES THEREOF IN THE TREATMENT OF LUPUS NEPHRITIS
#193Antibody-drug conjugate
#194Halogenated xanthene composition and method for treating hematologic cancers
#195HER2 ANTIBODY AND APPLICATION THEREOF
#196MODULATING THE IMMUNE RESPONSE USING ANTI-CD30 ANTIBODY-DRUG CONJUGATES
#197FC SILENCED ANTIBODY DRUG CONJUGATES (ADCS) AND USES THEREOF
#198METHODS OF INDUCING IMMUNE TOLERANCE WITH MODIFIED ANTI-CD154 ANTIBODIES
#199NANOLIPOPROTEIN-POLYPEPTIDE CONJUGATES AND COMPOSITIONS, SYSTEMS, AND METHODS USING SAME
#200Anti-CD40L antibodies and methods for treating CD40L-related diseases or disorders
#201METHODS AND SYSTEMS OF STRATIFYING INFLAMMATORY DISEASE PATIENTS
#202ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
#203CAR Cells and Polyspecific Binding Molecules for Treating Solid Tumor
#204METHODS AND COMPOSITIONS FOR DEPLETING NATURAL KILLER CELLS AND USES THEREOF IN CELLULAR THERAPIES
#205ANTIBODIES CONJUGATED OR FUSED TO THE RECEPTOR-BINDING DOMAIN OF THE SARS-COV-2 SPIKE PROTEIN AND USES THEREOF FOR VACCINE PURPOSES
#206CD70 combination therapy
#207ANTI-CD154 ANTIBODY HAVING IMPROVED BINDING, FUNCTIONAL AND SAFETY CHARACTERISTICS AND USE IN HUMAN IMMUNOTHERAPY
#208Therapeutic treatment of breast cancer based on c-MAF status
#209METHODS FOR DECREASING MORTALITY RISK AND IMPROVING HEALTH
#210STABILIZED ANTIBODY PROTEIN SOLUTIONS
#211ANTI-CD154 ANTIBODIES HAVING IMPAIRED FcR BINDING AND/OR COMPLEMENT BINDING PROPERTIES AND USE IN THERAPY
#212POLYPEPTIDE CONSTRUCTS BINDING TO CD3
#213ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO CD70, AND APPLICATION THEREOF
#214BIFUNCTIONAL ANTAGONISTS OF ACTIVIN/TGF-BETA AND RANKL AND USES THEREOF
#215MULTIPLEX GENE EDITED CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY
#216METHOD FOR TREATING OX40 RELATED DISEASE
#217NEUTRALIZING ANTI-TL1A MONOCLONAL ANTIBODIES
#218METHODS FOR CONCENTRATING PROTEINS
#219ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR B-CELL MATURATION ANTIGEN
#220SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF
#221CD70+ SOLID TUMOR THERAPY USING GENETICALLY ENGINEERED T CELLS TARGETING CD70
#222Treatment Of Arthropathy Based Upon Stratification Of Osteoarthritis Polygenic Risk Score
#223miR-3132 upregulation of the trail pathway and apoptotic activity in cancer cells
#224METHODS AND COMPOSITIONS RELATING TO EX VIVO CULTURE AND MODULATION OF T CELLS
#225TL1A THERAPY COMPOSITIONS AND METHODS OF TREATMENT THEREWITH
#226METHOD FOR MEASURING PHARMACOKINETICS OF AGENT LABELED WITH NON-RADIOACTIVE SUBSTANCE
#227METHODS OF TREATING AUTOIMMUNE DISEASE USING A DOMAIN ANTIBODY DIRECTED AGAINST CD40L
#228Anti-CD70 antibody drug conjugates
#229BI-FUNCTIONAL CHIMERIC PROTEINS AND USES THEREOF
#230ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS
#231INTRATUMORALLY INJECTED YEAST VACCINE
#232METHODS, SYSTEMS, AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TARGETING TL1A
#233THERAPEUTIC ANTIBODIES
#234TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES
#235Method of treating cancer using disulfide-linked trimeric OX40L
#236Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof
#237METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING A CANCER
#238ANTIBODIES TO CD70
#239Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence
#240ANTI-CD70 ANTIBODY AND APPLICATION THEREOF
#241AMH AND/OR INHIBIN B AS A BIOMARKER FOR AN EFFECT OF A TREATMENT TO IMPROVE MALE FERTILITY
#242MULTIMERS FOR VIRAL STRAIN EVOLUTION
#243Bifunctional molecule and use thereof
#244COMPOSITIONS COMPRISING A TN3 SCAFFOLD AND METHODS OF USING THE SAME
#245METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES
#246TREATMENT OF ATOPIC DERMATITIS
#247Multispecific antibodies, compositions comprising the same, and vectors and uses thereof
#248Anti-Blys Antibody for Treating Proteinuric Kidney Disease
#249PHARMACEUTICAL COMPOSITIONS WITH ANTI-RANKL ANTIBODIES, CALCIUM AND VITAMIN D
#250BISPECIFIC T CELL ENGAGING ANTIBODY CONSTRUCTS
#251OPTIMIZED ANTI-TL1A ANTIBODIES
#252METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES
#253PHARMACEUTICAL FORMULATION
#254PHARMACEUTICAL FORMULATION
#255METHODS AND COMBINATIONS FOR DUAL TARGETING OF TNF FAMILY MEMBERS
#256METHOD FOR THE PRODUCTION AND PURIFICATION OF MULTIVALENT IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#257BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
#258PROTEINS SPECIFIC FOR BAFF AND B7RP1 AND USES THEREOF
#259OX40-binding polypeptides and uses thereof
#260METHODS OF TREATING MULTIPLE MYELOMA
#261Antibodies binding CD70, preparation and use thereof
#262COMPOSITIONS COMPRISING A COMBINATION OF AN ANTI-LAG-3 ANTIBODY, A PD-1 PATHWAY INHIBITOR, AND AN IMMUNOTHERAPEUTIC AGENT
#263USE OF ANTIBODY DRUG CONJUGATES COMPRISING TUBULIN DISRUPTING AGENTS TO TREAT SOLID TUMOR
#264METHODS OF ADMINISTERING ANTI-OX40 ANTIBODIES
#265MULTIFUNCTIONAL MOLECULES THAT BIND TO CD33 AND USES THEREOF
#266COMPOSITIONS AND METHODS FOR TREATING DISORDERS CHARACTERIZED WITH EXCESSIVE OSTEOCLAST ACTIVITY
#267MITIGATION AND REVERSAL OF INTESTINAL FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION
#268INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#269MULTISPECIFIC ANTIBODIES, COMPOSITIONS COMPRISING THE SAME, AND VECTORS AND USES THEREOF
#270Triple combination antibody therapies
#271COMPOSITIONS AND METHODS FOR GAMMA DELTA TCR REPROGRAMMING USING FUSION PROTEINS
#272MULTISPECIFIC ANTIBODIES
#273Combination Treatments and Uses and Methods Thereof
#274CD40-L BLOCKADE TO ENHANCE SYNTHETIC ANTIBODY THERAPY
#275CATION EXCHANGE CHROMATOGRAPHY WASH BUFFER
#276Anti-CD30L antibodies and uses thereof
#277A METHOD OF ENGINEERING NATURAL KILLER CELLS TO TARGET CD70-POSITIVE TUMORS
#278DARPin based multi-specific t-cell engagers
#279Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
#280THERAPEUTIC ANTI-CD40 LIGAND ANTIBODIES
#281A COMBINATION OF, OR A BISPECIFIC BINDING MOLECULE TO, AN IMMUNE CHECKPOINT MOLECULE ANTAGONIST AND A RANK-L (NF-KB LIGAND) ANTAGONIST FOR CANCER THERAPY OR PROPHYLAXIS AND USES THEREOF
#282Chimeric antigen receptors targeting CD70
#283Antigen binding molecules that bind LIGHT
#284ANTIBODIES BINDING RANKL AND USES THEREOF
#285IMMUNOMODULATING TUMOR NECROSIS FACTOR RECEPTOR 25 (TNFR25) AGONISTS, ANTAGONISTS, AND IMMUNOTOXINS
#286THERAPEUTIC COMPOSITION AND ADMINISTRATION METHODS FOR INCREASING OSSEOINTEGRATION WITH DENTAL IMPLANTS, GRAFT MATERIALS AND PRF
#287Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody
#288Antibodies specific for CD70 and their uses
#289CD70 TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AND USES THEREOF
#290SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE
#291TUMOR NECROSIS FACTOR-LIKE LIGAND 1A SPECIFIC ANTIBODIES AND COMPOSITIONS AND USES THEREOF
#292ANTI-CD154 ANTIBODIES AND USES THEREOF
#293Anti-GDF15 antibodies, compositions and methods of use
#294SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
#295MULTISPECIFIC ANTIBODIES
#296Binding molecules for BCMA and CD3
#297Polypeptides comprising immunoglobulin single variable domains targeting IL-6 and TNF-α
#298IMMUNOGLOBULIN VARIABLE DOMAINS
#299IMMUNOGLOBULIN VARIABLE DOMAINS
#300METHODS OF B CELL EXPANSION FOR USE IN CELL THERAPY